Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Arexvy
Synonyms :
respiratory syncytial virus vaccine, adjuvanted
Class :
Inactivated Viral Vaccine
Brand Name :
Arexvy
Synonyms :
respiratory syncytial virus vaccine, adjuvanted
Class :
Inactivated Viral Vaccine
Dosage Forms & StrengthsÂ
injectable kit, antigen component in lyophilized form, and adjuvant suspension
0.5-mL
Respiratory Syncytial Virus (RSV)Â
Age: > 60 years
Indicated for Prevention of RSV Infection:
0.5
ml
Intramuscular (IM)
Single dose
Note:
Recommended for individuals aged sixty or older as active immunization against lower respiratory tract illness brought on by respiratory syncytial infection (RSV)
Respiratory Syncytial Virus (RSV)Â
Indicated for individuals aged sixty or older as active immunisation against lower respiratory tract illness brought on by respiratory syncytial infection (RSV)
:
A single dosage of 0.5 mL intramuscular
Safety and efficacy not establishedÂ
Refer adult dosingÂ
may increase the immunosuppressive effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
May decrease the diagnostic effect when combined with tuberculin Tests
May decrease the diagnostic effect when combined with tuberculin Tests
May decrease the diagnostic effect when combined with tuberculin Tests
May decrease the diagnostic effect when combined with tuberculin Tests
may decrease the therapeutic effect of Immunosuppressants
may decrease the therapeutic effect of Immunosuppressants
may decrease the therapeutic effect when combined
acetaminophen/doxylamine/dextromethorphanÂ
may decrease the therapeutic effect of acetaminophen
may diminish the therapeutic effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressants
tixagevimab and cilgavimab (Investigational)Â
may decrease the therapeutic effect of COVID-19 Vaccines
antithymocyte globulin equineÂ
may decrease the therapeutic effect of immunosuppressants
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
lansoprazole, amoxicillin, and clarithromycin
may decrease the therapeutic effect when combined with vaccine
may decrease the therapeutic effect when combined with vaccine
may decrease the therapeutic effect when combined with vaccine
may decrease the therapeutic effect when combined with vaccine
may decrease the therapeutic effect when combined with vaccine
may have a decreased therapeutic effect of influenza virus vaccines
may have a decreased therapeutic effect of influenza virus vaccines
may have a decreased therapeutic effect of influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with Vaccines
human rabies immune globulin (HRIG)
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with Vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may decrease the therapeutic effect when combined with influenza virus vaccines
may have an increased adverse/toxic effect when combined with immunosuppressants
may have an increased adverse/toxic effect when combined with immunosuppressants
may have an increased adverse/toxic effect when combined with immunosuppressants
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
The potential efficacy of vaccines may be reduced. (Inactivated/Non-Replicating)
fingolimod may diminish the therapeutic effect of vaccines (Inactivated/Non-Replicating)
may increase the toxic effect of Immunosuppressants
immunosuppressants decrease the efficacy of vaccines
immunosuppressants decrease the efficacy of vaccines
immunosuppressants decrease the efficacy of vaccines
immunosuppressants decrease the efficacy of vaccines
immunosuppressants decrease the efficacy of vaccines
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may reduce the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may diminish the therapeutic effect of vaccines
may decrease the therapeutic effect of Immunosuppressants
may decrease the therapeutic effect when combined with vaccines
may decrease the therapeutic effect when combined with vaccines
may decrease the therapeutic effect when combined with vaccines
may decrease the therapeutic effect when combined with vaccines
may decrease the therapeutic effect when combined with vaccines
Actions and Spectrum:Â
In the case of RSV vaccines, adjuvants may be included to help stimulate a more robust and durable immune response against the virus. The mechanism of action of an adjuvanted RSV vaccine would depend on the specific adjuvant used. However, adjuvants can help activate and enhance specific immune cells’ activity, such as antigen-presenting T and B cells. This can lead to a more robust and targeted immune response against the RSV virus.Â
The spectrum of activity of an adjuvanted RSV vaccine would also depend on the specific vaccine candidate being studied. Ideally, an RSV vaccine would protect against various RSV strains and subtypes, including those that cause severe disease. Developing an effective and safe RSV vaccine remains an active area of research. Further studies are needed to determine the optimal vaccine design and adjuvant strategy.Â
Frequency definedÂ
>10%Â
Fatigue, any grade (33.6%)Â
Headache, any grade (27.2%)Â
Pain, any grade (60.9%)Â
Myalgia, any grade (28.9%)Â
Arthralgia, any grade (18.1%)Â Â
1-10%Â
Swelling, >20 mm (5.5%)Â
Fatigue, Grade 3 (1.7%)Â
Headache, Grade 3 (1.3%)Â
Pain, Grade 3 (1%)Â
Erythema, >20 mm (7.5%)Â
Fever ≥38ÂşC/100.4ÂşF (2%)Â
Myalgia, Grade 3 (1.4%)Â
Arthralgia, Grade 3 (1.3%)Â Â
<1%Â
Swelling, >100 mm (0.2%)Â
Fever >39ÂşC/102.2ÂşF (0.1%)Â
Erythema, >100 mm (0.2%)Â
Contraindications/caution:Â
Contraindications:Â
As of May 2023, no approved respiratory syncytial virus (RSV) vaccine has been adjuvanted. Â
The possible contraindications or precautions to an adjuvanted RSV vaccine may include:Â
Caution:Â
Pregnancy consideration: Insufficient data availableÂ
It is not recommended for usage in those over 60 years oldÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
It is not recommended for usage in those over 60 years oldÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
The pharmacology of an adjuvanted RSV vaccine would depend on the specific vaccine candidate and adjuvant used. Vaccines generally work by introducing a small amount of an antigen (a substance that triggers an immune response) into the body, which stimulates the immune system to produce a specific response against that antigen. Adjuvants can help enhance the immune response and improve the vaccine’s effectiveness.Â
An adjuvanted RSV vaccine would likely contain one or more RSV antigens and an adjuvant that enhances the immune response to those antigens. The adjuvant may activate specific immune cells, such as antigen-presenting T and B cells, leading to a more robust and targeted immune response against the RSV virus.Â
Pharmacodynamics:Â
The pharmacodynamics of an adjuvanted RSV vaccine would depend on the specific vaccine candidate and adjuvant used. Vaccines generally produce a specific immune response against the targeted antigen(s). Adjuvants can enhance this immune response by activating immune cells and modulating the immune system’s response to the vaccine. Â
An adjuvanted RSV vaccine would stimulate the immune system to produce a targeted immune response against RSV. The specific antigens used in the vaccine would activate the immune system to produce antibodies and memory cells that recognize and respond to the virus if encountered in the future. The adjuvant would enhance this immune response by activating antigen-presenting T and B cells, leading to a more robust and targeted immune response against RSV.Â
The pharmacodynamics of an adjuvanted RSV vaccine would also depend on the vaccine schedule and the individual receiving the vaccine. For example, the immune response may vary depending on the number of doses administered, the timing, and the individual’s age, immune status, and overall health.Â
Pharmacokinetics:Â
AbsorptionÂ
After administration, the vaccine antigens and adjuvants would be absorbed into the bloodstream and distributed throughout the body, where they would stimulate an immune response. The specific route and Â
rate of absorption would depend on the vaccine formulation, the injection site, and the individual receiving the vaccine.Â
DistributionÂ
The vaccine distribution throughout the body would also depend on the specific vaccine formulation. Some vaccines may remain localized at the injection site. In contrast, others may be designed to disseminate more widely throughout the body.Â
MetabolismÂ
The metabolism and elimination of the vaccine antigens and adjuvants would depend on their specific chemical properties and their interactions with the body’s metabolic and immune systems. Enzymes in the liver or other organs may metabolize some vaccine components.Â
Elimination and ExcretionÂ
In contrast, others may be eliminated unchanged via the kidneys or other excretory pathways.Â
Administration:Â
The administration of an adjuvanted RSV vaccine would depend on the specific vaccine formulation and the healthcare provider’s recommendations. Vaccines are administered via injection, either subcutaneously (under the skin) or intramuscularly (into a muscle). The specific injection site may vary depending on the vaccine and the age of the individual receiving the vaccine.Â
The vaccine schedule for an adjuvanted RSV vaccine also depends on the specific vaccine formulation and the healthcare provider’s recommendations. Vaccines may be administered as a single dose or a series of doses over time. The number of doses and timing may vary depending on the vaccine and the individual receiving the vaccine.Â
Patient information leafletÂ
Generic Name:Â respiratory syncytial virus vaccine, adjuvantedÂ
 Why do we use respiratory syncytial virus vaccine, adjuvanted?Â
The potential uses of an adjuvanted RSV vaccine would be to prevent or reduce the incidence and severity of respiratory syncytial virus (RSV) infection. RSV is a common cause of respiratory illness in young children, older adults, and individuals with weakened immune systems. Occasionally, RSV infection can lead to severe respiratory illness, hospitalization, and even death, particularly in infants and young children.Â
An adjuvanted RSV vaccine would stimulate an immune response against the virus, producing antibodies and memory cells that recognize and respond to RSV. By reducing the incidence and severity of RSV infection, an adjuvanted RSV vaccine could help to prevent hospitalization, reduce healthcare costs, and improve the quality of life for individuals affected by RSV.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
